Previous 10 | Next 10 |
Today, we look at a small cap concern in the contraceptive space called Agile Therapeutics. The company recently had approved a potentially best of breed device in this niche that is just beginning its marketing rollout. A full investment analysis is provided in the paragraphs bel...
PRINCETON, N.J., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced Chairman and Chief Executive Officer Al Altomari will participate in a fireside chat at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference. ...
PRINCETON, N.J., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced the Company will present at the 39 th Annual J.P. Morgan Healthcare Conference, which is being held virtually, on Thursday, January 14, 2021, at...
Agile Therapeutics is preparing to launch their first FDA approved product, Twirla. If all goes well, Twirla could quickly establish a foothold in a $4.1B addressable market. Launching an FDA approved product is not easy and has plenty of unknowns. I point out some things to keep an e...
Are These On Your List Of Penny Stocks To Buy Right Now? The week has started mixed for broader markets but has that impacted all penny stocks today? In short, no and this has been the case forever. One of the attractions to these cheap stocks is that they tend to move on their own ...
Once-Weekly Twirla is the first and only contraceptive patch that combines levonorgestrel and ethinyl estradiol (EE) PRINCETON, N.J., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced the U.S. commerci...
Agile Therapeutics ([[AGRX]] -0.4%) says an international peer-reviewed reproductive health journal, Contraception, published the primary safety, efficacy, and tolerability results from the Phase 3 SECURE study evaluating Twirla transdermal system (AG200-15) which will als...
PRINCETON, N.J., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that Contraception , an international, peer-reviewed, reproductive health journal, published the primary safety, efficacy, and tolerability results f...
PRINCETON, N.J., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that Al Altomari, Chairman and Chief Executive Officer, will participate in a virtual fireside chat at the Piper Sandler 32 nd Annual Healthcare...
Investors can't complain about Agile Therapeutics ' (NASDAQ: AGRX) stock performance so far this year. The drugmaker's shares are up nearly 17% year to date after a strong rebound from the market meltdown in the first quarter of 2020. Agile announced its third-quarter results af...
News, Short Squeeze, Breakout and More Instantly...
Agile Therapeutics Inc. Company Name:
AGRX Stock Symbol:
OTCMKTS Market:
Agile Therapeutics Inc. Website:
First Quarter Net Revenue Increased 58% and Factory Sales Increased 3% from Fourth Quarter 2023 Twirla First Quarter 2024 Demand Rebounded 18% from Fourth Quarter 2023 PRINCETON, N.J., May 15, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Pink: AGRX), a women's healthcare com...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
Full Year 2023 Net Revenue Increased 80% from 2022 While OPEX Decreased 33% Twirla Demand and Factory Sales Up 121% and 114% Respectively in 2023 vs 2022 Company Completes Pay-Off of Debt Facility in First Quarter 2024 Twirla Demand Expected to Rebound in First Quarter 2...